Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis

Patients with primary biliary cholangitis (PBC) with incomplete response to ursodeoxycholic acid are at risk of disease progression and need additional therapy. Obeticholic acid (OCA) was approved in Canada in May 2017, but its effectiveness in a real‐world setting has not been described. We sought...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberts, Surain B., Ismail, Marwa, Kanagalingam, Gowthami, Mason, Andrew L., Swain, Mark G., Vincent, Catherine, Yoshida, Eric M., Tsien, Cynthia, Flemming, Jennifer A., Janssen, Harry L.A., Hirschfield, Gideon M., Hansen, Bettina E., Gulamhusein, Aliya F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471421/
https://www.ncbi.nlm.nih.gov/pubmed/32923836
http://dx.doi.org/10.1002/hep4.1518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471421/
https://www.ncbi.nlm.nih.gov/pubmed/32923836
http://dx.doi.org/10.1002/hep4.1518

Ejemplares similares